Toxicology – Sulfonamides

Core Concept

Sulfonamides include several antimicrobial drugs and related compounds. Important examples include:

• Sulfamethoxazole, most commonly combined with trimethoprim as TMP-SMX
• Sulfadiazine
• Sulfadoxine
• Sulfacetamide
• Silver sulfadiazine
• Mafenide
• Sulfasalazine — primarily used for inflammatory bowel disease and some rheumatologic conditions

Many older sulfonamides are now rarely used.

Acute isolated overdose is usually relatively mild. More clinically important toxicity generally occurs as an adverse reaction during therapeutic use, particularly:

• Hypersensitivity
• Severe cutaneous adverse reactions
• Hematologic toxicity
• Renal injury
• Hepatotoxicity
• Hyperkalemia from the trimethoprim component of TMP-SMX
• Hypoglycemia in susceptible patients
• Rare methemoglobinemia or hemolysis

There is no universal specific antidote for sulfonamide poisoning.

Mechanism of Antimicrobial Action

Sulfonamide antibiotics inhibit bacterial folate synthesis by competing with para-aminobenzoic acid (PABA) and inhibiting dihydropteroate synthase.

Trimethoprim acts at a different step by inhibiting dihydrofolate reductase.

Therefore, TMP-SMX produces sequential inhibition of microbial folate metabolism.

Acute Overdose

Most isolated acute sulfonamide ingestions produce either no symptoms or relatively nonspecific GI effects such as:

• Nausea
• Vomiting
• Abdominal discomfort

Severe acute toxicity is uncommon.

Importantly, many of the most serious sulfonamide reactions are not directly related to the size of an overdose.

1. Hypersensitivity

Sulfonamide antimicrobials can cause immune-mediated reactions at therapeutic doses.

Possible manifestations include:

• Fever
• Maculopapular rash
• Urticaria
• Angioedema
• Drug fever
• Rare anaphylaxis

A susceptible individual can react after relatively small exposure, so there is no meaningful “safe overdose threshold” for allergic reactions.

Severe Cutaneous Adverse Reactions

Sulfonamide antibiotics are important causes of severe drug eruptions, including:

• Stevens–Johnson syndrome (SJS)
• Toxic epidermal necrolysis (TEN)
• DRESS
• AGEP

These are primarily delayed adverse drug reactions rather than manifestations of acute overdose.

SJS/TEN

Warning features include:

• Fever
• Malaise
• Painful skin
• Blistering
• Epidermal detachment
• Oral erosions
• Ocular involvement
• Genital mucosal involvement

Suspected SJS/TEN requires:

Immediate discontinuation of the causative drug + urgent hospital assessment + supportive specialist care

Simply treating the eruption as an uncomplicated “sulfa allergy” can miss a life-threatening syndrome.

DRESS

Drug reaction with eosinophilia and systemic symptoms may produce:

• Fever
• Extensive rash
• Facial edema
• Eosinophilia
• Lymphadenopathy
• Hepatitis
• Nephritis
• Other organ involvement

Symptoms may continue or evolve even after the medication has been discontinued.

“Sulfa Allergy” – Important Clarification

A history of allergy to a sulfonamide antimicrobial does not automatically mean that the patient will cross-react with every medication containing a sulfonamide chemical group.

Non-antimicrobial sulfonamide-containing drugs are structurally different.

Therefore:

“Sulfa allergy” should not automatically be interpreted as allergy to all sulfur-containing or sulfonamide-containing medications.

Elemental sulfur, sulfates, and sulfites are also chemically distinct from sulfonamide antibiotics.

2. Renal Toxicity

Sulfonamides are substantially eliminated through the kidneys, and renal impairment can increase systemic exposure to some agents.

Renal complications include:

• Crystalluria
• Crystal nephropathy
• Hematuria
• Acute interstitial nephritis
• Acute kidney injury

Crystalluria

Some sulfonamides or their metabolites have limited urinary solubility.

Precipitation within the urinary tract can produce:

Crystalluria → tubular obstruction/injury → hematuria → AKI

Risk may increase with:

• High exposure
• Dehydration
• Concentrated urine
• Preexisting renal dysfunction

Modern agents are generally less prone to severe crystalluria than some older sulfonamides, but the complication remains possible.

Acute Interstitial Nephritis

Sulfonamides can cause immune-mediated interstitial nephritis.

Possible findings include:

• Rising creatinine
• Hematuria
• Pyuria
• Proteinuria

Fever, rash, and eosinophilia may occur but are not reliably present.

TMP-SMX and Creatinine – Important Pitfall

Trimethoprim can inhibit tubular secretion of creatinine.

Therefore, serum creatinine may rise even without a true fall in GFR.

This can create an apparent AKI.

However, TMP-SMX can also cause genuine renal injury, so a creatinine increase should not automatically be dismissed as a benign laboratory effect.

Interpret:

• Creatinine trend
• Urine output
• Urinalysis
• Electrolytes
• Overall clinical condition

3. Hyperkalemia

A major modern toxicity omitted from many older sulfonamide discussions is trimethoprim-associated hyperkalemia.

Trimethoprim can act similarly to the potassium-sparing diuretic amiloride in the distal nephron.

This decreases renal potassium excretion.

Therefore:

Trimethoprim → reduced K⁺ excretion → hyperkalemia

Risk Factors for TMP-SMX Hyperkalemia

Risk increases with:

• Renal impairment
• Older age
• High trimethoprim exposure
• Baseline hyperkalemia
• ACE inhibitors
• ARBs
• Potassium-sparing diuretics
• Other medications that impair potassium elimination

Severe hyperkalemia can cause:

• Weakness
• Conduction abnormalities
• Ventricular dysrhythmia
• Cardiac arrest

Hyperkalemia Management

Clinically important hyperkalemia should be managed according to severity and ECG findings.

Priorities include:

• Stop contributing medications
• Cardiac stabilization when indicated
• Shift potassium intracellularly
• Promote potassium elimination
• Consider dialysis for severe refractory hyperkalemia or major renal failure

The serum potassium level and clinical/ECG picture are more important than the size of the original antibiotic exposure.

4. Hematologic Toxicity

Sulfonamides can rarely cause:

• Neutropenia
• Agranulocytosis
• Thrombocytopenia
• Pancytopenia
• Hemolytic anemia

These are generally complications of therapeutic exposure rather than isolated acute ingestion.

Hemolysis and G6PD Deficiency

Sulfonamide antimicrobials can produce oxidative stress.

Patients with G6PD deficiency may be more susceptible to hemolysis.

Possible findings include:

• Fatigue
• Pallor
• Jaundice
• Dark urine
• Falling hemoglobin
• Elevated bilirubin
• Elevated LDH
• Reduced haptoglobin

The risk varies by drug, dose, and individual susceptibility.

5. Methemoglobinemia

Methemoglobinemia is an uncommon but recognized complication of some sulfonamide exposures.

Oxidation converts hemoglobin iron:

Fe²⁺ → Fe³⁺

Methemoglobin cannot effectively carry oxygen.

Clinical Features of Methemoglobinemia

Possible findings include:

• Cyanosis
• Headache
• Dizziness
• Dyspnea
• Fatigue
• Tachycardia

Severe cases may cause:

• Altered consciousness
• Myocardial ischemia
• Seizures
• Dysrhythmias
• Cardiovascular collapse

Diagnosis of Methemoglobinemia

A characteristic clue is:

Low pulse oximetry that improves little despite supplemental oxygen

Blood may appear unusually dark or brownish.

Diagnosis is confirmed using co-oximetry.

Standard pulse oximetry alone cannot accurately quantify methemoglobin.

Treatment of Methemoglobinemia

Management includes:

• Stop the oxidizing drug
• Supplemental oxygen
• Support airway and circulation
• Treat clinically significant symptomatic methemoglobinemia with an appropriate reducing agent such as methylene blue

Treatment decisions depend on:

• Symptoms
• Methemoglobin concentration
• Comorbid disease
• Evidence of tissue hypoxia

A rigid concentration alone should not determine treatment.

Methylene Blue – Important Caution

Methylene blue requires particular caution in patients with G6PD deficiency because:

• Response may be reduced
• Hemolysis may worsen

It can also contribute to serotonergic toxicity because it has monoamine oxidase-inhibiting properties.

Severe cases in which methylene blue is ineffective or unsuitable require specialist toxicology/hematology input.

6. Hypoglycemia

Sulfonamide antimicrobial therapy, especially TMP-SMX, can occasionally cause hypoglycemia.

Risk increases with:

• Renal impairment
• Malnutrition
• Older age
• High systemic exposure
• Concurrent glucose-lowering medications

Manifestations include:

• Sweating
• Tremor
• Confusion
• Altered consciousness
• Seizures

Check bedside glucose in patients with neurologic symptoms.

7. Hepatotoxicity

Sulfonamide antibiotics can cause drug-induced liver injury.

Patterns may include:

• Hepatocellular injury
• Cholestatic injury
• Mixed injury

Liver involvement can also occur as part of systemic hypersensitivity or DRESS.

Clinical Features of Liver Injury

Possible findings include:

• Fatigue
• Nausea
• Right-upper-quadrant discomfort
• Pruritus
• Dark urine
• Jaundice

Evaluation may include:

• AST/ALT
• Bilirubin
• Alkaline phosphatase
• Coagulation studies when severe

8. Pulmonary Hypersensitivity

Rare pulmonary reactions include:

• Drug-induced pneumonitis
• Eosinophilic pulmonary reactions
• Other hypersensitivity lung injury

Symptoms may include:

• Cough
• Dyspnea
• Fever
• Hypoxemia

Alternative infectious and cardiopulmonary causes must also be considered.

9. Sulfasalazine

Sulfasalazine deserves separate consideration because it is metabolized in the colon to:

• 5-aminosalicylic acid
• Sulfapyridine

Therefore, its toxicity is not identical to ordinary sulfonamide antimicrobial poisoning.

Possible adverse effects include:

• Nausea
• Vomiting
• Abdominal discomfort
• Headache
• Rash
• Hepatotoxicity
• Hematologic toxicity
• Rare hemolysis
• Rare severe hypersensitivity

Large exposures may also have features related to its salicylate-derived component, although classic severe salicylate poisoning should not automatically be assumed.

10. Topical Sulfonamides

Silver Sulfadiazine

Used particularly for selected burn/wound indications.

Systemic absorption can occur when applied to large areas of damaged skin.

Potential complications include:

• Leukopenia
• Hypersensitivity
• Rare systemic sulfonamide effects

Mafenide

Mafenide is particularly important because it can inhibit carbonic anhydrase.

Systemic absorption from large treated burn areas can contribute to:

Bicarbonate loss → hyperchloremic metabolic acidosis

This is an important agent-specific toxicity not emphasized in older general sulfonamide summaries.

11. Neonates and Bilirubin

Sulfonamides have historically raised concern for displacement of bilirubin from albumin binding.

Neonates—particularly premature infants or those with significant hyperbilirubinemia—require special caution because excessive unbound bilirubin can contribute to bilirubin encephalopathy/kernicterus.

This concern is primarily relevant to systemic therapeutic exposure in susceptible neonates rather than typical accidental overdose in older children.

Pregnancy and Breastfeeding

The old FDA pregnancy letter categories are obsolete.

Use during pregnancy should be individualized according to:

• Specific drug
• Gestational timing
• Infection
• Maternal condition
• Folate considerations
• Available alternatives

TMP-SMX deserves particular consideration because trimethoprim interferes with folate metabolism.

Near delivery, neonatal bilirubin-related considerations may also influence drug selection.

Breastfeeding

Sulfonamide use during breastfeeding should consider:

• Infant age
• Prematurity
• Hyperbilirubinemia
• G6PD status
• Specific medication

A blanket statement that all sulfonamides are either completely safe or universally contraindicated during breastfeeding is inappropriate.

Diagnosis

Determine:

• Exact product
• Whether trimethoprim is also present
• Amount
• Timing
• Acute vs prolonged exposure
• Renal function
• Other medications
• Allergy history
• Coingestants

The distinction between isolated sulfonamide exposure and TMP-SMX is particularly important because trimethoprim contributes additional renal and electrolyte effects.

Laboratory Evaluation

Small asymptomatic exposures may require no testing.

For significant or symptomatic toxicity, consider:

• Bedside glucose
• CBC
• Electrolytes
• Potassium
• Bicarbonate
• BUN/creatinine
• Urinalysis
• Liver tests

Depending on presentation:

• Co-oximetry for suspected methemoglobinemia
• Hemolysis studies
• ECG for hyperkalemia or significant systemic illness
• Blood gas when severe acid–base disturbance is suspected

Serum Sulfonamide Concentrations

Routine serum sulfonamide concentrations are generally not clinically useful.

Management should be guided by:

• Symptoms
• Renal function
• Electrolytes
• Hematologic findings
• Organ injury

Initial Management

General priorities are:

Airway/breathing → circulation → identify exact drug → glucose → electrolytes/renal function → evaluate hypersensitivity and organ toxicity → supportive care

Most isolated acute ingestions do not require aggressive intervention.

GI Decontamination

Do not induce vomiting.

Ipecac has no modern role.

Routine gastric lavage is obsolete.

Activated charcoal may occasionally be considered after a substantial recent ingestion when:

• The drug is adsorbable
• The airway is safe
• Aspiration risk is acceptable
• Expected clinical benefit justifies treatment

Many uncomplicated exposures require no decontamination.

Anaphylaxis

If true anaphylaxis occurs:

IM epinephrine is first-line therapy.

Provide:

• Airway support
• Oxygen when required
• Appropriate IV fluid resuscitation
• Additional supportive treatment

Antihistamines may help skin symptoms but must not delay epinephrine.

Seizures

For toxicologic seizures:

Benzodiazepines are first-line.

Persistent seizures may require additional benzodiazepines, phenobarbital, or appropriate anesthetic management.

Correct accompanying:

• Hypoglycemia
• Electrolyte abnormalities
• Hypoxia
• Acid–base disturbances

Hypotension

Determine whether hypotension reflects:

• Anaphylaxis
• Dehydration
• Severe hypersensitivity
• Coingestion
• Other illness

Treat appropriate volume depletion with isotonic crystalloid.

Persistent vasodilatory shock generally favors norepinephrine.

Trendelenburg positioning and routine dopamine-first therapy are outdated.

Renal Management

When crystalluria or renal injury is suspected:

• Stop further exposure
• Correct dehydration appropriately
• Monitor renal function
• Monitor urine output
• Correct electrolyte abnormalities
• Avoid additional nephrotoxins where possible

Aggressive forced diuresis is not routinely appropriate.

Enhanced Elimination

Hemodialysis is not routine treatment for uncomplicated sulfonamide overdose.

It may become relevant when severe toxicity occurs in the setting of:

• Major renal failure
• Severe refractory electrolyte abnormalities
• Other conventional indications for renal replacement therapy

The decision should be individualized.

Monitoring

Monitoring should match the toxicity.

Renal toxicity

• Creatinine
• Electrolytes
• Potassium
• Urine output

Hematologic toxicity

• CBC
• Hemolysis studies when indicated

Hepatotoxicity

• Liver tests
• Coagulation studies if severe

Methemoglobinemia

• Clinical oxygenation
• Co-oximetry

Severe hypersensitivity

• Skin/mucosal progression
• Airway
• Hemodynamics
• Organ involvement

Observation and Disposition

There is no universal observation period.

Disposition depends on:

• Exact drug
• Amount
• Symptoms
• Renal function
• Potassium/glucose abnormalities
• Coingestants
• Clinical trajectory

Importantly, delayed immune reactions such as SJS/TEN, DRESS, cytopenias, or hepatitis cannot be excluded by a few hours of emergency observation.

Admission

Hospitalization may be required for:

• Anaphylaxis
• SJS/TEN or other severe cutaneous reaction
• DRESS with organ involvement
• Significant methemoglobinemia
• Hemolysis
• Severe cytopenia
• AKI
• Significant hyperkalemia
• Severe hypoglycemia
• Hepatic injury
• Persistent seizures
• Hemodynamic instability

ICU or specialized burn/critical-care management may be necessary for severe SJS/TEN, shock, respiratory failure, or major methemoglobinemia.

Safeguarding

Rigid historical age thresholds for assuming neglect, abuse, or intentional poisoning are outdated.

Pediatric exposures should instead be assessed according to:

• Developmental capability
• Medication accessibility
• Circumstances
• Consistency of history
• Recurrent unexplained exposures
• Broader safeguarding concerns

Prognosis

Most isolated acute sulfonamide ingestions recover with supportive care.

Prognosis is more serious when toxicity involves:

• SJS/TEN
• DRESS
• Severe anaphylaxis
• Agranulocytosis
• Severe hemolysis
• Methemoglobinemia
• Significant AKI
• Hyperkalemia
• Severe hepatic injury

Important Modernization of the Older Source

• Acute sulfonamide overdose is usually mild, while serious toxicity more often represents therapeutic adverse reactions.
• Hypersensitivity is not reliably dose dependent; severe reactions can occur at therapeutic doses.
• Sulfonamide antimicrobials are important causes of SJS/TEN and DRESS.
• “Sulfa allergy” does not automatically imply cross-allergy to every non-antibiotic sulfonamide, sulfate, sulfite, or sulfur-containing substance.
• TMP-SMX must be considered as a two-drug exposure.
• Trimethoprim can cause clinically important hyperkalemia.
• Trimethoprim may raise serum creatinine by reducing tubular creatinine secretion without necessarily reducing true GFR.
• Sulfonamides can also cause true AKI through crystal nephropathy or interstitial nephritis.
• G6PD deficiency may increase susceptibility to oxidative hemolysis.
• Methemoglobinemia is rare but potentially serious; diagnosis is by co-oximetry.
• Methylene blue requires special caution in G6PD deficiency and can interact with serotonergic medications.
• Mafenide can cause hyperchloremic metabolic acidosis through carbonic-anhydrase inhibition.
• Neonatal kernicterus concerns are primarily relevant to susceptible premature or hyperbilirubinemic infants.
• Ipecac and routine gastric lavage are obsolete.
• Forced diuresis is not routine treatment for crystalluria.
• Trendelenburg and dopamine-first shock management are outdated.
• Historical FDA pregnancy letter categories are obsolete.
• Delayed hypersensitivity, marrow, liver, and renal complications cannot be excluded by a short observation period.

Key Points

• Sulfonamides → hypersensitivity, renal, hematologic, and hepatic toxicity.
• TMP-SMX → remember trimethoprim-associated hyperkalemia and creatinine elevation.
• SJS/TEN and DRESS are major delayed adverse reactions.
• Crystalluria, interstitial nephritis, and true AKI can occur.
• G6PD deficiency increases concern for oxidative hemolysis.
• Rare methemoglobinemia is confirmed with co-oximetry.
• Mafenide → hyperchloremic metabolic acidosis.
• Sulfonamide allergy does not equal allergy to all sulfur-containing drugs.
• There is no single specific antidote for sulfonamide poisoning.
• Management is primarily withdrawal of the offending drug, supportive care, and targeted treatment of complications.